Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (opens the original source in a new tab)
New England Journal of Medicine
- Design
- Phase 2, double-blind, randomised, placebo-controlled trial; 48 weeks. Primary endpoint at week 24.
- Population / setting
- Adults with obesity, or overweight plus at least one weight-related condition.
- Sample size
- n = 338
What was observed
The highest studied arm had mean weight change of −17.5% at the primary 24-week endpoint versus −1.6% with placebo. At the secondary 48-week endpoint, changes were −24.2% versus −2.1%. Gastrointestinal events and increases in heart rate were reported.
Keep in view
This phase 2 result estimates effects in the studied arms and population, not an approved indication or a long-term cardiovascular outcome. The frequently quoted 24.2% is a secondary 48-week result, not the primary endpoint. Funded by Eli Lilly.
WHY THIS SOURCE IS HERE
- Retatrutide and Gastrointestinal Side Effects: Reading Tolerability Results
Understand what trial reports mean by gastrointestinal events, severity and treatment discontinuation.
- Retatrutide Safety Signals: Heart Rate, Sensation Changes and Unanswered Questions
Separate observed safety findings from causation and understand what longer follow-up must clarify.